Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677313 | 1.00 | LTA4H (0.47) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 | |
| SCHEMBL3315632 | 1.00 | LTA4H (0.47) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 | |
| SCHEMBL24960955 | 0.95 | FKBP1A (0.52) | LTA4HFKBP1APOLBALDH1A1KDM4E | |
| SCHEMBL15114560 | 0.95 | FKBP1A (0.52) | LTA4HFKBP1APOLBALDH1A1KDM4E | |
| SCHEMBL24960953 | 0.95 | FKBP1A (0.52) | LTA4HFKBP1APOLBALDH1A1KDM4E | |
| SCHEMBL2773153 | 0.89 | FKBP1A (0.42) | LTA4HFKBP1APOLBALDH1A1GAA | |
| SCHEMBL9649182 | 0.86 | FKBP1A (0.51) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 | |
| SCHEMBL18482504 | 0.86 | FKBP1A (0.51) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 | |
| SCHEMBL10182480 | 0.86 | FKBP1A (0.51) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 | |
| SCHEMBL4681706 | 0.85 | LTA4H (0.47) | LTA4HFKBP1APOLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117185977-A | Preparation method of amisulpride intermediate | 江苏阿尔法药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023006019-A1 | POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015161309-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | ZHOU JIA (US) | 2015-10-22 | — | — | WO | disclosed |
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2008106619-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| WO-2007081540-A2 | TYLOPHORINE ANALOGS AS ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | OXTR, AVPR2, AVPR1B | LTA4H 3773/4885FKBP1A 580/4885POLB 4809/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | LTA4H 2929/4885FKBP1A 921/4885POLB 1161/4885 |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | KCNH2, KCNH3, KCNJ2 | LTA4H 1464/4885FKBP1A 3926/4885POLB 4568/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | LTA4H 441/4885FKBP1A 781/4885POLB 4104/4885 |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | RPL30, RPL18A, RPP30 | LTA4H 674/4885FKBP1A 3122/4885POLB 3424/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | LTA4H 2929/4885FKBP1A 921/4885POLB 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.